Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: A systematic review and indirect comparison of safety and efficacy

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 11, 2013, Pages 1917-1926

  Dranitsaris, George ^a,b   Schmitz, Susanne ^c   J Broom, Reuben ^d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Trinity College ^*  (Canada)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Axitinib; Everolimus; Indirect comparison; Pazopanib; Renal cell carcinoma; Sorafenib

Indexed keywords

AXITINIB; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; NICOTINAMIDE; PYRIMIDINE DERIVATIVE; RAPAMYCIN; SULFONAMIDE;

ARTICLE; BAYES THEOREM; CANCER CONTROL; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; KIDNEY METASTASIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; SKIN MANIFESTATION; STOMATITIS; SYSTEMATIC REVIEW; TOXICITY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; META ANALYSIS; METABOLISM;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CARCINOMA, RENAL CELL; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; SULFONAMIDES;

EID: 84892677470     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1510-5     Document Type: Article

References (32)

1. Broglio KR, Berry DA (2009) Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649
2. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198-1220
3. Cai T, Parast L, Ryan L (2010) Meta-analysis for rare events. Stat Med 29:2078-2089
4. Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333-339
5. DiLorenzoG,CascianoR,Malangone E et al (2011)An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinibrefractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 12:1491-1497
6. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in metastatic clear cell carcinoma. N Engl J Med 356:125-134
7. Escudier B, Eisen T, Stadler WM et al (2009a) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
8. Escudier B, Szczylik C, Hutson TE et al (2009b) Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289
9. Escudier B, Eisen T, Porta C et al (2012a) Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii65-vii71
10. Escudier B, Szczylik C, Porta C, Gore M (2012b) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9:327-337
11. Grünwald V, Kalanovic D, Merseburger AS (2010) Management of sunitinib-related adverse events: an evidence and expert-based consensus approach. World J Urol 28:343-351
12. Hutson TE, Bellmunt J, Porta C et al (2010) Long-term safety of sorafenib in metastatic renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 46:2432-2440
13. Larkin J, Paine A, Tumur I et al (2013) Second-line treatments for the management of metastatic renal cell carcinoma: systematic review and meta-analysis. Expert Opin Pharmacother 14:27-39
14. Levy A, Menard J, Albiges L, Loriot Y et al (2013) Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. Eur J Cancer 49:1898-1904
15. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23:3105-3124
16. Mills EJ, Rachlis B, O'Regan C, Thabane L, Perri D (2009) Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 27(9):34
17. Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. New Engl J Med 335:865-875
18. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against metastatic renal cell carcinoma. J Clin Oncol 20:289-296
19. Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463
20. Motzer MJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356:115-124
21. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in metastatic clear cell carcinoma: a double blind randomized placebo controlled phase III trial. Lancet 372:449-456
22. Motzer RJ, Escudier B, Tomczak P et al (2013) Axitinib versus sorafenib as second-line treatment for metastatic renal cell carcinoma: overall survival analysis and updated results from a randomized phase 3 trial. Lancet Oncol 14:552-562
23. National Cancer Institute of Canada (2012) Canadian Cancer Statistics 2012. Toronto, Canada (http://www.cancer.ca). Accessed 23 May 2013
24. Nelson EC, Evans CP, Lara PN Jr (2007) Renal cell carcinoma: current status and emerging therapies. Cancer Treat Rev 33:299-313
25. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in metastatic renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931-1939
26. Roskoski R Jr (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323-328
27. Sonpavde G, Hutson TE, Rini BI (2008) Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 17:741-748
28. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally metastatic or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061-1068
29. Surveillance Epidemiology and End Results (SEER) (2013) National Cancer Institute 2012. Washington, USA (http://seer.cancer.gov/ statfacts/html/lungb. html). Accessed 23 May 2013
30. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumours: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
31. Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127
32. Wong MK, Mohamed AF, Hauber AB et al (2012) Patients rank toxicity against progression free survival in second-line treatment of metastatic renal cell carcinoma. J Med Econ 15:1139-1148